Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
8,649 people get TEVA articles and Market Currents by email alert.
Get email alerts on TEVA »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Galena Biopharma: David Battles GoliathRegarded Solutions • Wed, Jun 19 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Teva's CEO Reviews Management Succession (Transcript)Tue, Jan 3, 2012
-
Teva CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Feb 8, 2011 • 1 Comment
-
Teva Pharmaceutical Industries Limited Q2 2010 Earnings Call TranscriptTue, Jul 27, 2010 • 1 Comment
-
Business Wire (Mon, 9:30AM)
-
at Fox Business (Thu, 4:02PM)
-
at CNBC.com (Wed, 5:25PM)
-
Business Wire (Wed, 4:06PM)
-
at Fox Business (Jun 12, 2013)
-
at CNBC.com (Jun 12, 2013)
-
Business Wire (Jun 12, 2013)
-
Business Wire (Jun 12, 2013)
-
at MarketWatch.com (Jun 11, 2013)
-
Business Wire (May 30, 2013)
-
Business Wire (May 14, 2013)
-
at CNBC.com (May 9, 2013)
-
at CNBC.com (May 8, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 2, 2013)
-
at CNBC.com (Apr 26, 2013)
TEVA vs. ETF Alternatives
Company Description
Teva Pharmaceutical Industries Limited (“Teva”) is a global pharmaceutical company that develops, produces and markets generic drugs in all major therapeutic categories. We are the leading generic drug company in the world – with the leading position in the U.S. (in terms of both value and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, December 7, 2012, 4:41 AM The Supreme Court could say today whether it will review a case involving a "pay for delay" agreement in which a pharmaceutical company pays generic rivals tens of millions of dollars to hold off from launching copycat versions of medicines. The FTC says the practice costs customers $3.5B a year, while drug firms argue that it protects innovation. Companies that could be affected include Abbott (ABT), Watson (WPI), Merck (MRK), Bristol-Myers Squibb (BMY) and Teva (TEVA). Comment! [Healthcare, Top Stories]
- Tuesday, December 4, 2012, 10:11 AM The patent cliff has been good for generic-drugs companies this year, with over 40 brand-name treatments with $35B of annual sales losing their IP protection. However, the sector faces its own patent cliff over the next couple of years, due to fewer drugs losing that protection. In response, the generic companies are specializing in treatments that are hard to make, selling their own branded medicines, or making big acquisitions. 1 Comment [Healthcare]
- Tuesday, December 4, 2012, 8:24 AM Galena (GALE) soars 17.2% after signing a deal with Teva (TEVA) for the commercialization of its NeuVax breast cancer treatment in Israel. While financial terms weren't disclosed, Teva will make significant royalty payments to Galena on future sales. Israel will be the location of at least four sites for Phase 3 trials of NeuVax. Comment! [On the Move, Healthcare]
- Friday, November 30, 2012, 7:09 AM Teva Pharmaceutical (TEVA) forecasts 2013 EPS of $4.85-$5.15 against Street expectations for $5.63. Total revenue is expected at $19.5B-$20.5B. Shares -5.5% premarket. (PR) 2 Comments [Healthcare, On the Move, Breaking News]
- Wednesday, November 28, 2012, 4:47 PM Rexahn Pharmaceuticals (RNN) says it intends to offer shares of its common stock and warrants in an underwritten public offering. The shares are being offered as units, with no amount given at present. Earlier today the company announced it would be receiving additional funding from Teva Pharmaceutical (TEVA) for the development of its potential tumor treatment RX-3117. Burrill and Maxim Group are acting as joint book-running mangers for the offering. Comment! [Healthcare]
- Wednesday, November 28, 2012, 12:53 PM Rexahn Pharmaceuticals (RNN +9%) trades higher after the company said that Teva Pharmaceutical (TEVA -0.6%) will provide an additional $750K in funding to the company. Pursuant to the terms of an earlier agreementl, TEVA will purchase RNN's common stock at 120% of its closing price on the last trading day preceding the closing. TEVA has also agreed to commit additional research funding for development of RX-3117, a potential treatment for solid tumors including colon, lung and pancreatic cancers, and will retain the right to file the Investigational New Drug application with the FDA. 2 Comments [Healthcare, On the Move]
- Tuesday, November 27, 2012, 3:00 PM Teva Pharmaceuticals (TEVA +0.9%) agrees to delay the introduction of generic versions of two Gilead (GILD -0.9%) HIV drugs, Truvada and Viread, until June 1 or until a judge rules on the patent fight between the two companies. GILD sued TEVA in 2008 and again in 2010, claiming its FDA applications to make HIV drugs infringed four of its patents. The complaints also listed the HIV drug Atripla, which wasn’t cited in today’s filing. Comment! [Healthcare, On the Move]
- Wednesday, November 21, 2012, 8:50 AM Teva (TEVA) is putting a freeze on the type of multi-billion dollar acquisitions that have spurred its growth, Chairman Phillip Frost indicates, unless something something "so compelling and so game-changing" crops up. Instead, "there is the opportunity for product acquisitions, for small company acquisitions, for technology acquisitions," Frost says. 1 Comment [Healthcare, M&A]
- Tuesday, November 20, 2012, 9:40 AM While multiple-sclerosis patients have waited years for pills to be developed to treat the debilitating disease, doctors are warning them to be wary. That's because drugs such as Novartis' (NVS) Gilenya and Sanofi's (SNY) Aubagio can have significant side-effects. All of which is positive for Teva (TEVA), whose Copaxone is injected rather than taken orally. 4 Comments [Healthcare]
- Tuesday, November 20, 2012, 9:20 AM While multiple-sclerosis patients have waited years for pills to be developed to treat the debilitating disease, doctors are warning them to be wary. That's because drugs such as Novartis' (NVS) Gilenya and Sanofi's (SNY) Aubagio can have significant side-effects. All of which is positive for Teva (TEVA), whose Copaxone is injected rather than taken orally. Comment! [Healthcare]
- Thursday, November 15, 2012, 8:28 AM Amarin (AMRN) +9% following a report that Teva (TEVA +0.7%) is leading the race to acquire the Irish biotech, which has a market cap of $1.6B, with AstraZeneca (AZN +0.4%) also in the hunt. Teva recently said it wasn't intending to make any major acquisitions, while it's also due to unveil a long-term overhaul in December. 3 Comments [Healthcare, On the Move, M&A]
- Monday, November 12, 2012, 1:14 PM E.U. regulators have approved Procter & Gamble's (PG +0.2%) acquisition of Teva's (TEVA +0.1%) over-the-counter business, saying it doesn't raise any competitive concerns. The agency had looked closely at the impact on markets for topical anti-rheumatics, analgesics and expectorants - particularly in the Baltic countries - but found no anti-trust risks. 4 Comments [Healthcare, Global & FX]
- Thursday, November 8, 2012, 10:24 AM Pfizer's (PFE -0.2%) Viagra patent has been ruled no longer valid by Canada's top court, backing an appeal by generic drug maker Teva Pharmaceutical (TEVA +0.1%) that claimed PFE hadn't provided sufficient details when it initially filed its patent registration. 1 Comment [Healthcare]
- Monday, November 5, 2012, 10:20 AM Teva (TEVA -1.4%) makes a few management changes to its executive leadership team, appointing SVP Allan Oberman to President and CEO of Teva Americas Generics, replacing current chief executive William Marth who will step down and retire at the end of 2013. The company also promotes Jill DeSimone to the newly created position of SVP and General Manager of Teva Global Women’s Health franchise. Ms. DeSimone is a seasoned veteran in specialty medicine franchising, and will manage all aspects of building the business. Comment! [Healthcare]
- Thursday, November 1, 2012, 2:16 PM Teva (TEVA +2%) discloses in a regulatory filing that the DoJ has sent an informal request for documents regarding possible violations of the Foreign Corrupt Practice Act in Latin America. The company had already received a subpoena in July from the SEC on the matter and says it's cooperating with the government. TEVA says it's also launched a voluntary investigation into certain business practices which may have FCPA implications. Comment! [Healthcare]
- Thursday, November 1, 2012, 8:17 AM More on Teva (TEVA) Q3: swings to net loss of $79M from profit of $916M last year, due to $670M provision connected to patent litigation and $481M impairment mostly related to R&D. U.S. sales +33% to $2.6B, boosted by the acquisition of Cephalon. Europe sales +13% in local currencies. Copaxone revenue +13% to $1.05B. Narrows 2012 guidance range to $5.32-$5.38 for EPS and $20.1B-$20.7B for revenue, both in line. 3 Comments [Healthcare, Earnings]
-
- View all 3 replies
-
-
-
FortSumter
TEVA Bought Oct $42.50 calls for $15. Pointed out by 1980 the 25k volume just for today at that strike. Gambling. - View all 0 replies
-
- View all 8 replies
-
-
FortSumter: Quick math shows 26K @100 shares per to tie up almost 3% of the available shares for a one day event. Hmmmmm.
-
- View all 0 replies
-
Michael Bryant
Watson Pharma (ACT) may be the best generic drug stock besides Teva Pharma (TEVA), Taro Pharma (TARO), and Indian maker Dr. Reddies (RDY). - View all 0 replies
-
Saibus Research
Teva: Undervalued Industry Leading Generic Drug Maker At 7.5X Adjusted EPS http://seekingalpha.com/a/gx39 $TEVA - View all 2 replies
-
Mercy Jimenez: Agree but watch entry price; testing results, Israeli/ Iran jitters etc.have swung to $35 recently; I add as it hits $37-39 during meltdowns -
Saibus Research: Mercy, not a bad entry point. Healthcare sector undervalued relative to its historical multiples and has held up well in the last few months
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES